Brenda Banwell, a pediatric neuroimmune specialist, presented findings from the OPERETTA 2 study on the safety and efficacy of ocrelizumab for pediatric-onset multiple sclerosis (POMS) at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. While more than 25 treatments are approved for adults with multiple sclerosis, options for children remain limited. #pediatric #multiplesclerosis #johnshopkins https://www.hopkinschildrens.org/ms